期刊文献+

含1,2,3-三氮唑基团的新型四氧杂杯[2]芳烃[2]嘧啶衍生物的合成与抗肿瘤活性研究

Synthesis and Antitumor Activities of Novel Tetraoxacalix[2]arene[2]pyrimidine Derivatives Containing 1,2,3-Triazole Groups
下载PDF
导出
摘要 以4-氯-2-甲硫基-6-丙炔氧基嘧啶为原料,依次经Williamson醚合成、氧化和聚合反应制得新型四氧杂杯[2]芳烃[2]嘧啶母体(4),并通过点击化学反应合成了4个结构新颖的含1,2,3-三氮唑基团的四氧杂杯[2]芳烃[2]嘧啶衍生物(5a^5d),其结构经1H MNR,13C MNR和HR-MS(ESI)表征。采用MTT法研究了5a^5d对人宫颈癌细胞(Hela),人乳腺癌细胞(MCF-7),人肝癌细胞(HepG2)和人肺癌细胞(A549)的体外抗肿瘤活性。结果表明:化合物5a对MCF-7具有明显的抑制活性,在50μM浓度下抑制率可达82%,优于阳性对照药5-氟尿嘧啶。 Four novel tetraoxacalix[2]arene[2]pyrimidine parent substance was prepared from 4-chloro-2-methylthio-6-propynyloxypyrimidine via Williamson ether synthesis,oxidation and polymerization reactions,which finally afforded four novel tetraoxacalix[2]arene[2]pyrimidine derivatives(5 a^5 d)containing 1,2,3-triazole groups via click chemistry.The structures were characterized by 1H MNR,13C MNR and HR-MS(ESI).The antitumor activities of 5 a^5 d against human cervical cancer cells(Hela),human breast cancer cells(MCF-7),human hepatoma cells(HepG2),and human lung cancer cells(A549)were evaluated by MTT assays.The results showed that 5 a exhibited significant inhibitory activity against MCF-7 with 82%inhibition rate at a concentration of 50μM,which was superior to the positive control 5-Fluorouracil.
作者 吴鑫 余永波 安琳 黄统辉 WU Xin;YU Yong-bo;AN Lin;HUANG Tong-hui(Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy,Xuzhou Medical University,Xuzhou 221000,China)
出处 《合成化学》 CAS 北大核心 2020年第5期393-397,共5页 Chinese Journal of Synthetic Chemistry
基金 江苏省自然科学基金资助项目(BK20171184) 江苏省研究生科研与实践创新项目(KYCX18-2203)。
关键词 芳烃[2]嘧啶 点击化学 合成 1 2 3-三氮唑 抗肿瘤活性 tetraoxo[2]arene[2]pyrimidine click chemistry synthesis 1,2,3-triazole antitumor activity
  • 相关文献

参考文献3

二级参考文献30

  • 1P. Carmeliet, Angiogenesis in health and disease, Nat. Med. 9 (2003) 653-660.
  • 2N. Ferrara, R.S. Kerbel, Angiogenesis as a therapeutic target, Nature 438 (2005) 96?-9?4.
  • 3Z.K. Otrock, J.A. Makarem, A.I. Shamseddine, Vascular endothelial growth factor family of ligands and receptors: review, Blood Cells. Mol. Dis. 38 (20071258-268.
  • 4A. Garofalo. A. Farce, S. Ravez, et al., Synthesis and structure-activity relationships of (Aryloxy) quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors, J. Med. Chem. 55 (20121 1189-1204.
  • 5K. Sanphanya, S.K. Wattanapitayakul, S. Phowichit, V.V. Fokin, O. Vajragupta, Novel VEGFR-2 kinase inhihitors identified by the back-to-front approach, Bioorg. Med. Chem. Lett. 23 (2013) 2962-296?.
  • 6H.M.W. Verheul, H.M. Pinedo, Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nat. Rev. Cancer 7 (2007) 475-485.
  • 7R.A. Brekken, J.P. Overholser, V.A. Stastny, et al., Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/FIk-1) activity by a monoclonal anti-VECF antibody blocks tumor growth in mice, Cancer Res. 60 (2000) 5117- 5124.
  • 8X.W. Zhao, D. Liu, S.L. Luan, et al., Synthesis and biological evaluation of substi- tuted 1,2,3-benzotriazines and pyrido[M][3,2-d]-l,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2, Bioorg. Med. Chem. 21 (2013) 7807-7815.
  • 9T.A. Fong, L.K. Shawver, L. Sun, et al., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res. 59 (1999) 99-106.
  • 10S. Wilhelm, C. Carter, M. Lynch, et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat. Rev. Drug Discov. 5 (2006) 835-844.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部